Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 8/20 | 0.61 |
| ▸ | PIM1 | P11309 | 7/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.53 |
| ▸ | PDE5A | O76074 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | C1R | P00736 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259264 | 0.87 | PDE5A (0.54) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL259307 | 0.81 | TNKS2 (0.56) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL259214 | 0.80 | TNKS (0.49) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL259304 | 0.78 | PIK3CA (0.54) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL21180249 | 0.73 | PDE5A (0.58) | CSNK2A2CSNK2BPDE5AAURKAFGFR1 | |
| SCHEMBL259329 | 0.73 | TNKS (0.42) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL13318878 | 0.73 | PIM1 (0.40) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL7162893 | 0.72 | GUSB (0.70) | PDE5AGUSBTNKSTNKS2PARP2 | |
| SCHEMBL259271 | 0.72 | PIM1 (0.44) | CSNK2A2CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL29740691 | 0.72 | GUSB (0.78) | GUSBTNKSTNKS2PARP2C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | CSNK2A2 237/4885CSNK2B 253/4885PIM1 865/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | CSNK2A2 237/4885CSNK2B 253/4885PIM1 865/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | CSNK2A2 237/4885CSNK2B 253/4885PIM1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.